ArticleNucleic acids research2004
LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1.
Article in Nucleic acids research, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 96 citations in OpenAlex.
- Are we there yet with XNA aptamers?RSC advances · 2026Review
- Supramolecular Nucleic Acid-Based Organosilica Nanoparticles Responsive to Physical and Biological Inputs.Journal of the American Chemical Society · 2023Article
- Design of LNA Analogues Using a Combined Density Functional Theory and Molecular Dynamics Approach for RNA Therapeutics.ACS omega · 2023Article
- Advances in Aptamer-Based Biosensors and Cell-Internalizing SELEX Technology for Diagnostic and Therapeutic Application.Biosensors · 2022Review
- XNAs: A Troubleshooter for Nucleic Acid Sensing.ACS omega · 2022Review
- Nucleic Acids and Their Analogues for Biomedical Applications.Biosensors · 2022Review
- DNA/RNA Fluorescence Imaging by Synthetic Nucleic Acids.Advances in experimental medicine and biology · 2021Article
- Aptamers as a novel diagnostic and therapeutic tool and their potential use in parasitologyBiomedica : revista del Instituto Nacional de Salud · 2020Review
- Aptamers Chemistry: Chemical Modifications and Conjugation Strategies.Molecules (Basel, Switzerland) · 2019Review
- Perspective on the Future Role of Aptamers in Analytical Chemistry.Analytical chemistry · 2019Article
- Aptamers Selected for Recognizing Amyloid β-Protein-A Case for Cautious Optimism.International journal of molecular sciences · 2018Review
- Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes.International journal of molecular sciences · 2017Review
- Aptamers against pathogenic microorganisms.Critical reviews in microbiology · 2016Review
- Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers.International journal of molecular sciences · 2016Review
- Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.Nucleic acids research · 2014Article
- Molecular beacons of xeno-nucleic acid for detecting nucleic acid.Theranostics · 2013Review
- Aptamers and the next generation of diagnostic reagents.Proteomics. Clinical applications · 2012Review
- Inhibition of HIV Replication by Cyclic and Hairpin PNAs Targeting the HIV-1 TAR RNA Loop.Journal of nucleic acids · 2012Article
- Locked and unlocked nucleosides in functional nucleic acids.Molecules (Basel, Switzerland) · 2011Article
- Essential structural requirements for specific recognition of HIV TAR RNA by peptide mimetics of Tat protein.Nucleic acids research · 2011Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the major limitations of the use of phosphodiester oligonucleotides in cells is their rapid degradation by nucleases. To date, several chemical modifications have been employed to overcome this issue but insufficient efficacy and/or specificity have limited their in vivo usefulness. In this work conformationally restricted nucleotides, locked nucleic acid (LNA), were investigated to design nuclease resistant aptamers targeted against the HIV-1 TAR RNA. LNA/DNA chimeras were synthesized from a shortened version of the hairpin RNA aptamer identified by in vitro selection against TAR. The results indicate that these modifications confer good protection towards nuclease digestion. Electrophoretic mobility shift assays, thermal denaturation monitored by UV-spectroscopy and surface plasmon resonance experiments identified LNA/DNA TAR ligands that bind to TAR with a dissociation constant in the low nanomolar range as the parent RNA aptamer. The crucial G, A residues that close the aptamer loop remain a key structural determinant for stable LNA/DNA chimera-TAR complexes. This work provides evidence that LNA modifications alternated with DNA can generate stable structured RNA mimics for interacting with folded RNA targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.